Results 71 to 80 of about 983,540 (218)

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Vaccines, 2023
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines.
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan   +16 more
doaj   +1 more source

mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern

Immunity, 2022
SARS-CoV-2 mRNA vaccines confer robust protection against COVID-19, but the emergence of variants has generated concerns regarding the protective efficacy of the currently approved vaccines, which lose neutralizing potency against some variants. Emerging
P. Kaplonek, S. Fischinger, D. Cizmeci, Y. Bartsch, Jaewon Kang, J. Burke, Sally A. Shin, D. Dayal, Patrick Martin, Colin J. Mann, F. Amanat, B. Julg, E. Nilles, E. Musk, A. S. Menon, F. Krammer, E. Saphire, A. Carfi, G. Alter   +18 more
semanticscholar   +1 more source

Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database [PDF]

, 2023
Introduction: Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily ...
Bonaldo G., Broccoli M., Montanaro N., Motola D., Santi Laurini G.   +4 more
core   +1 more source

mRNA-1273 [PDF]

, 2021

  +6 more sources

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient. [PDF]

, 2022
We report a case of recurrent tender, multifocal lymphadenopathies associated with B-symptoms, clinically mimicking lymphoma in a mRNA-1273 vaccine recipient after a recent Epstein-Barr virus (EBV) infection.
Girardin, F.R., Greub, G., Livio, F., Pantaleo, G., Tzankov, A.   +4 more
core   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge [PDF]

, 2021
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of SARS and MERS coronavirus vaccines. We used the SARS-CoV-2 MA10 mouse model of acute lung injury to evaluate the immune response and potential ...
Abiona, O.M., Alvarado, G.S., Baric, R.S., Bock, K.W., Boyoglu-Barnum, S., Carfi, A., Chang, L.A., Corbett, K.S., Dinnon, K.H., III, DiPiazza, A.T., Edwards, D.K., Graham, B.S., Leist, S.R., Loomis, R.J., Mascola, J.R., Minai, M., Moliva, J.I., Moore, I.N., Morabito, K.M., Nagata, B.M., Phung, E., Ruckwardt, T.J., Schäfer, A., Sullivan, N.J., Werner, A.   +24 more
core   +2 more sources

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations

medRxiv, 2022
Two messenger RNA (mRNA)-based vaccines are widely used globally to prevent coronavirus disease 2019 (COVID-19). Both vaccine formulations contain PEGylated lipids in their composition, in the form of polyethylene glycol [PEG] 2000 dimyristoyl glycerol ...
J. Carreño, Gagandeep Singh, J. Tcheou, K. Srivastava, C. Gleason, Hiromi Muramatsu, Parnavi Desai, J. Aberg, Rachel L. Miller, P. study group, N. Pardi, V. Simon, F. Krammer   +12 more
semanticscholar   +1 more source

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial

Annals of Internal Medicine, 2022
Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2.
D. Follmann, H. Janes, O. Buhule, Honghong Zhou, B. Girard, K. Marks, K. Kotloff, Michaël Desjardins, L. Corey, K. Neuzil, Jacqueline M. Miller, Hana M. El Sahly, L. Baden   +12 more
semanticscholar   +1 more source